- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Waldenstrom macroglobulinemia
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 1.5MB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 795KB)
Zanubrutinib – March 2022
Zanubrutinib: Capsule 80 mg; Brukinsa®
Last updated
1 July 2022